Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases

Colin Holtze; Kevin Flaherty; Michael Kreuter; Fabrizio Luppi; Teng Moua; Carlo Vancheri; Mary B Scholand

doi:10.1183/16000617.0078-2018

Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases

Eur Respir Rev. 2018 Dec 21;27(150):180078. doi: 10.1183/16000617.0078-2018. Print 2018 Dec 31.

Authors

Colin Holtze^{1

2}, Kevin Flaherty³, Michael Kreuter⁴, Fabrizio Luppi⁵, Teng Moua⁶, Carlo Vancheri⁷, Mary B Scholand^{8

2}

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA choltze@med.umich.edu.
² Both authors contributed equally.
³ Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
⁴ Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, member of the German Center for Lung Research, Heidelberg, Germany.
⁵ Centre for Rare Lung Disease, University Hospital, Modena, Italy.
⁶ Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
⁷ Dept of Clinical and Experimental Medicine, University of Catania, University Hospital "Policlinico - Vitt. Emanuele", Catania, Italy.
⁸ Dept of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.

Abstract

There are over 200 interstitial lung diseases (ILDs). In addition to patients with idiopathic pulmonary fibrosis (IPF), a percentage of patients with other ILDs also develop progressive fibrosis of the lung during their disease course. Patients with progressive-fibrosing ILDs may show limited response to immunomodulatory therapy, worsening symptoms and lung function and, ultimately, early mortality. There are few data for ILDs that may present a progressive fibrosing phenotype specifically, but we believe the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF. This review discusses the burden of ILDs that may present a progressive fibrosing phenotype and the factors impacting healthcare utilisation.

Publication types

Review

MeSH terms

Comorbidity
Disease Progression
Health Care Costs*
Humans
Lung Diseases, Interstitial / diagnosis
Lung Diseases, Interstitial / economics*
Lung Diseases, Interstitial / mortality
Lung Diseases, Interstitial / therapy*
Phenotype
Pulmonary Fibrosis / diagnosis
Pulmonary Fibrosis / economics*
Pulmonary Fibrosis / mortality
Pulmonary Fibrosis / therapy*
Risk Factors
Treatment Outcome